Metropolis Healthcare (NSE:METROPOLIS) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:METROPOLIS Metropolis Healthcare Ltd NSE:METROPOLIS
95 GF Score
Price ₹567.95
GF Value ₹588.25
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Metropolis Healthcare Research & Development?

Metropolis Healthcare NSE:METROPOLIS +1.41% 95 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 95/100 and a GF Value™ of ₹588.25 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Metropolis Healthcare's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Metropolis Healthcare  (NSE:METROPOLIS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Metropolis Healthcare Research & Development Related Terms

Metropolis Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Metropolis Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metropolis Healthcare Research & Development Chart

Metropolis Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Metropolis Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:METROPOLIS
95GF Score
Metropolis Healthcare Ltd NSE:METROPOLIS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metropolis Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Metropolis Healthcare (NSE:METROPOLIS) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Metropolis Healthcare and its competitors.
Is Metropolis Healthcare's Research & Development too high?
Metropolis Healthcare's current Research & Development is ₹0 Mil. Overall, Metropolis Healthcare has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's Research & Development compare to TMO and DHR?
Metropolis Healthcare's Research & Development of ₹0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Metropolis Healthcare and its competitors. Metropolis Healthcare's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.25, compared to a current price of ₹567.95 — trading 3.5% below its estimated fair value. The current Research & Development is ₹0 Mil. Metropolis Healthcare's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?

Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued. The current stock price of ₹567.95 is trading 3.5% below its estimated GF Value™ of ₹588.25. GuruFocus considers Metropolis Healthcare to be Fairly Valued.

Key valuation signals for NSE:METROPOLIS:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹588.25 vs. price of ₹567.95 (3.5% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Metropolis Healthcare Business Description

Other Exchanges 542650:India
Address Dr. Annie Besant Road, 4th Floor, East Wing, Plot-254 B, Nirlon House, Worli, Mumbai, MH, IND, 400 030
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
95GF Score

Get the complete analysis for NSE:METROPOLIS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹567.95
Price
₹588.25
GF Value